In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.
The antimicrobial activity of CP-62,993 against four Chlamydia trachomatis isolates was compared with those of erythromycin, clindamycin, and tetracycline. The MIC of CP-62,993 was 0.26 to 1.02 micrograms/ml for 100% inclusion inhibition and 0.031 to 0.063 microgram/ml for 50% inclusion inhibition. With pharmacokinetic and antimicrobial studies demonstrating prolonged half-life and in vitro effectiveness, CP-62,993 may make possible a single, short-course treatment regimen for C. trachomatis infection.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin; D002692:Chlamydia trachomatis / Q000187:drug effects*; D002981:Clindamycin / Q000494:pharmacology; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D004917:Erythromycin; D017963:Azithromycin; D013752:Tetracycline